LIFUS-POT: Modulating Cerebellar Activity With Low-intensity Focused Ultrasound Stimulation for Primary Orthostatic Tremor

Sponsor
University Health Network, Toronto (Other)
Overall Status
Recruiting
CT.gov ID
NCT05547620
Collaborator
National Organization for Rare Disorders (Other)
15
1
1
36
0.4

Study Details

Study Description

Brief Summary

Primary orthostatic tremor (POT) is a rare movement disorder that is manifested through high frequency tremor of weight bearing limbs. This is often accompanied by a debilitating sensation of falling. POT has been linked to abnormal activity of the cerebellum, a structure deep within the brain. However, established non-invasive brain stimulation techniques can only modulate brain activity and plasticity in superficial brain areas with low spatial resolution. This limits their efficacy when targeting the cerebellum. In contrast, low intensity focused ultrasound (LIFUS) is a novel non-invasive brain stimulation technique that permits stimulation with high spatial focality and can reach greater depth compared other methods. Therefore, LIFUS is well suited to modulate cerebellar activity and has the potential to be a superior technique for the management of POT. This study will investigate the effectiveness of MRI-guided bilateral cerebellar LIFUS stimulation for the treatment of POT and evaluate the underlying changes in brain circuits caused by the stimulation. Comparisons between symptoms and connectivity of brain circuits pre- and post-stimulation will be conducted to assess the effects of cerebellar LIFUS. The effects of real stimulation will also be compared to sham stimulation. This study is the first to apply LIFUS for neuromodulation in POT and will be critical in developing therapeutic LIFUS protocols.

Condition or Disease Intervention/Treatment Phase
  • Device: LIFUS Online Real
  • Device: LIFUS Online Sham
  • Device: LIFUS Offline
N/A

Detailed Description

In the current study the investigators aim to assess the effects of low intensity focused ultrasound (LIFUS) on the symptoms of primary orthostatic tremor (POT) and on brain connectivity. LIFUS is a promising non-invasive brain stimulation technique that is actively being studied for its ability to reversibly modulate brain activity. By focusing the propagation of acoustic wave through the skull, a higher degree of spatial specificity and deep targeting can be achieved over other non-invasive stimulation methods such as transcranial magnetic stimulation (TMS) and transcranial direct-current stimulation (tDCS). Specifically, investigators will use LIFUS to stimulate the cerebellum bilaterally for 80s per hemisphere using a theta burst protocol that investigators have shown to induce plasticity. Investigators hypothesize that modulating cerebellar activity will decrease symptoms of POT and normalize the dysfunctional cerebello-thalamo-cortico network. 15 POT patients will be recruited to participate in 3 sessions in-lab. The first visit will involve an anatomical magnetic resonance image (MRI) scan. This will allow us to accurately target cerebellar lobule VIII and establish the appropriate parameters of LIFUS to effectively pass through the skull. In visits 2 and 3 participants will be seated in a comfortable chair and an anatomical MRI image will be used to position the LIFUS transducer over cerebellar lobule VIII bilaterally on surface of their head. In visit 2, clinical assessments of POT will be conducted through electromyography (EMG) recordings and video analysis of posture and sway. Symptoms prior to and after LIFUS will be compared. Investigators will compare the effects of real stimulation to a sham stimulation. In visit 3, Investigators will assess brain network activity using transcranial magnetic stimulation (TMS) by employing an established paired-pulse paradigm. This method will allow us to establish the effects of LIFUS on the cerebello-thalamo-cortical network and determine how this related to changes observed in POT symptoms.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Modulating Dysfunctional Cerebellar Activity With Low-intensity Focused Ultrasound Stimulation for Primary Orthostatic Tremor
Actual Study Start Date :
Mar 8, 2021
Anticipated Primary Completion Date :
Mar 8, 2024
Anticipated Study Completion Date :
Mar 8, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low Intensity Focused ultrasound

NeuroFUS device stimulation with 4 channel transducer Stimulation target = Cerebellum

Device: LIFUS Online Real
Stimulation using NeuroFUS device while standing

Device: LIFUS Online Sham
Stimulation using NeuroFUS device while standing

Device: LIFUS Offline
Stimulation using NeuroFUS device prior to standing

Outcome Measures

Primary Outcome Measures

  1. Tremor frequency [2 Years]

    The primary outcomes will consist of peak tremor frequency recorded from surface electromyography (EMG). The EMG electrodes will be placed on the skin, and electrical activity produced by muscle contractions will be recorded. From the recordings of EMGs, peak frequency will be extracted through statistical analyses.

  2. Power spectral analysis [2 Years]

    Power spectrum recorded from surface electromyography (EMG). The EMG electrodes will be placed on the skin, and electrical activity produced by muscle contractions will be recorded. From the recordings of EMGs, power spectrum will be extracted through statistical analyses.

  3. Orthostatic Tremor Severity and Disability Scale (OT-10) [2 Years]

    The Orthostatic Tremor Severity and Disability Scale (OT-10) is a self-administered 10-item scale that measures the severity and disability of orthostatic tremor. Each item is rated from 0-5, with higher scores representing worse outcome.

Secondary Outcome Measures

  1. Assessment of body posture [2 Years]

    Posture during standing will be video recorded and analyzed using Kinovea, an analysis software for evaluation of human movements that express measurements in figures, tables, and graphics. Specifically, posture analysis will be carried out by measuring the alignment of the head, shoulder, hips, knees, and ankles. Deviation scores for each alignment measure will be calculated and averaged to calculate an overall alignment deviation score for each participant.

  2. Standing time [2 Years]

    Duration of standing

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18-80 years of age

  • Confirmed diagnosis of orthostatic tremor

Exclusion Criteria:
  • History of stroke or seizure

  • Comorbid dementia

  • Scored below 22 on the Montreal Cognitive Assessment (MoCA)

  • Has intracranial implant(s) or device(s)

  • Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)

  • Has a previous surgical intervention to treat the movement disorder such as lesioning or a deep brain stimulation (DBS) system in place.

  • Presence of metal implanted in body that is contraindicated in TMS/MRI

  • Pregnancy

  • Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study

  • Is on antipsychotics, marijuana, or other recreational drugs that affect the nervous system

  • Major musculoskeletal or neuromuscular disease or disorder of the hands, wrists and limbs

  • Major systemic illness or infection

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toronto Western Hospital Toronto Ontario Canada M5T 2S8

Sponsors and Collaborators

  • University Health Network, Toronto
  • National Organization for Rare Disorders

Investigators

  • Principal Investigator: Robert Chen, MBBS, University Health Network, Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Robert Chen, Senior Scientist, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT05547620
Other Study ID Numbers:
  • 20-5740
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 28, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2022